Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Why Cannabis Stocks are Recession Proof

Oct 13, 2016 • 12:47 PM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Earnings season is starting to heat up and so far it has been unimpressive at best. Companies continue to cite weakness as a result of weaker global demand and a stronger dollar, and we expect this to be a theme of this earnings season.

The combination of weak earnings, slowing demand, and poor economic data, will create a great opportunity for an investor to buy quality companies at a discount…but you need to know where to look.

The markets are trading lower this morning after China registered its steepest monthly drop in its exports since February, with a 10% year-on-year contraction compared with expectations for a 3.3% decline.

Although we expect this trend to continue, we want to highlight stocks that we are monitoring for a buy opportunity on further weakness.

GW Pharmaceuticals (GWPH)

GW Pharmaceuticals continues to be our top pick in the cannabis sector and we are favorable on the company for the following reasons: 1) It continues to receive positive Wall Street coverage, 2) Its deep pipeline of products will create catalysts for years to come, 3) It possesses valuable intellectual property that makes it a very expensive acquisition target, and 4) The shares are trading below the average Wall Street price target.

We continue to believe that GW will be one of the greatest beneficiaries from the legalization of medical cannabis and the shares are a perfect vehicle for anyone who wants to enter the legal medical cannabis sector but is still hesitant to do so.

Aurora Cannabis (ACB) (ACBFF)

Throughout 2016, we have continued to recommend Aurora Cannabis (ACB) (ACBFF) as the Street continued to undervalue the company’s stock. Aurora’s Canadian symbol, ACB, and its United States symbol, ACBFF, have rallied more than 200% since late August and we continue to hold onto the shares in our mock portfolio.

We remain favorable on Aurora at current levels for the following reasons: 1) It continues to strengthen its management team and board, 2) It is bringing on new patients at industry leading rates, 3) It is building a 600,000 sq. ft. facility that will have an estimated annual production capacity of over 70,000 kg of cannabis, 4) Its financial position continues to improve, 5) The company recently commenced trading on the TSX Venture Exchange and we expect to see them up-list to the TSX in 2017, and 5) We expect the company to report that it is cash-flow positive before the end of the year.

MassRoots (MSRT)

MassRoots is one of the largest and most active technology platforms for cannabis consumers, businesses and activists. The social network formed in April 2013 as an online community for people who smoke cannabis.

We are favorable on MSRT and see upside to current levels because of the following reasons: 1) It continues to advance its platform and create new avenues for revenue growth, 2) It has entered into strategic partnerships that has improved and differentiated its product when compared to its competition, 3) The election will serve as a catalyst as it will increase the number of active users on its platform, 4) The company’s cost cutting initiatives have strengthened its balance sheet and improved its financial position, 5) It started monetizing its platform and revenue has grown significantly since it started, and 6) Its valuation has improved.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.